Kenvue (NYSE:KVUE) PT Lowered to $22.00 at JPMorgan Chase & Co.

Kenvue (NYSE:KVUE) had its target price decreased by JPMorgan Chase & Co. from $23.00 to $22.00 in a research report report published on Monday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Several other research analysts have also recently issued reports on KVUE. William Blair started coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a market perform rating on the stock. Citigroup reduced their price objective on shares of Kenvue from $21.00 to $20.00 and set a neutral rating for the company in a research note on Wednesday, July 10th. HSBC upped their target price on Kenvue from $20.00 to $21.00 and gave the stock a hold rating in a report on Wednesday, May 8th. Finally, Sanford C. Bernstein began coverage on Kenvue in a research report on Thursday, April 11th. They issued an underperform rating and a $18.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Hold and an average price target of $22.82.

Kenvue Trading Up 1.3 %

Shares of KVUE stock opened at $18.17 on Monday. The company has a market cap of $34.79 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 2.00 and a beta of 1.40. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The stock’s 50 day simple moving average is $18.67 and its two-hundred day simple moving average is $19.59. Kenvue has a 1 year low of $17.67 and a 1 year high of $25.23.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.25 by $0.03. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The company had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. The firm’s revenue was down 24.9% compared to the same quarter last year. Research analysts predict that Kenvue will post 1.13 earnings per share for the current year.

Hedge Funds Weigh In On Kenvue

Hedge funds have recently bought and sold shares of the company. Manchester Capital Management LLC increased its position in shares of Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the last quarter. Planned Solutions Inc. acquired a new position in shares of Kenvue during the fourth quarter worth $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in Kenvue in the fourth quarter valued at $28,000. Mather Group LLC. acquired a new stake in Kenvue in the first quarter valued at $28,000. Finally, Oakworth Capital Inc. purchased a new stake in Kenvue during the 1st quarter worth about $31,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.